APHINITY试验6年随访:早期HER2阳性乳腺癌辅助帕妥珠单抗与曲妥珠单抗
APHINITY试验的第二次预先计划中期总生存(OS)分析和描述性更新无侵袭性疾病生存(IDFS)分析,中位随访74个月。IDFS风险比为0.76(95%CI 0.64-0.91),6年IDFS分别为91%和88%。淋巴结阳性 cohort 持续获益(HR 0.72),淋巴结阴性 cohort 未见获益。
要点
- 帕妥珠单抗组6年IDFS为91%,安慰剂组为88%,HR 0.76(95%CI 0.64-0.91)。
- 淋巴结阳性患者持续IDFS获益(HR 0.72,95%CI 0.59-0.87),淋巴结阴性者无获益。
核心结论
- 在淋巴结阳性HER2阳性早期乳腺癌中,辅助帕妥珠单抗联合曲妥珠单抗和化疗可带来IDFS获益。
- OS获益尚未达到统计学显著性,需要更长随访。
研究设计与样本
- 随机、双盲、安慰剂对照的III期试验,纳入4805例淋巴结阳性或高风险淋巴结阴性HER2阳性早期乳腺癌患者。
- 患者术后按1:1随机接受1年帕妥珠单抗或安慰剂,联合标准辅助化疗和1年曲妥珠单抗。
- 本次分析为中位随访74个月的第二次预先计划 interim OS 分析和描述性更新IDFS分析。
主要发现
- IDFS分析基于508起事件(意向治疗人群),帕妥珠单抗组与安慰剂组相比HR为0.76(95%CI 0.64-0.91),6年IDFS分别为91%和88%。
- 淋巴结阳性 cohort 的IDFS HR为0.72(95%CI 0.59-0.87),6年IDFS分别为88%和83%。
- 淋巴结阴性 cohort 未观察到IDFS获益。
- 亚组分析中,激素受体阳性疾病的IDFS HR为0.73(95%CI 0.59-0.92),激素受体阴性疾病的HR为0.83(95%CI 0.63-1.10)。
关键数值与推荐
- IDFS获益:总体人群HR 0.76(95%CI 0.64-0.91),6年IDFS 91% vs 88%。
- 淋巴结阳性人群IDFS HR 0.72(95%CI 0.59-0.87),6年IDFS 88% vs 83%。
- 主要心脏事件发生率两组均<1%。
临床怎么用
- 对于淋巴结阳性HER2阳性早期乳腺癌患者,辅助帕妥珠单抗联合曲妥珠单抗和化疗可改善IDFS。
- 淋巴结阴性患者未显示IDFS获益,需个体化评估。
- OS获益尚不明确,需继续随访。
局限性
- OS分析为中期分析,未达到统计学显著性,需要更长随访。
- 淋巴结阴性 cohort 未观察到获益,但该 cohort 样本量可能有限。
- 亚组分析为探索性,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: APHINITY, at 45 months median follow-up, showed that pertuzumab added to adjuvant trastuzumab and chemotherapy significantly improved invasive disease-free survival (IDFS) (hazard ratio 0.81 [95% CI, 0.66 to 1.00], P = .045) for patients with early human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC), specifically those with node-positive or hormone receptor (HR)-negative disease. We now report the preplanned second interim overall survival (OS) and descriptive updated IDFS analysis with 74 months median follow-up. METHODS: After surgery and central HER2-positive confirmation, 4,805 patients with node-positive or high-risk node-negative BC were randomly assigned (1:1) to either 1-year pertuzumab or placebo added to standard adjuvant chemotherapy and 1-year trastuzumab. RESULTS: This interim OS analysis comparing pertuzumab versus placebo did not reach the P = .0012 level required for statistical significance (P = .17, hazard ratio 0.85). Six-year OS were 95% versus 94% with 125 deaths (5.2%) versus 147 (6.1%), respectively. IDFS analysis based on 508 events (intent-to-treat population) showed a hazard ratio of 0.76 (95% CI, 0.64 to 0.91) and 6-year IDFS of 91% and 88% for pertuzumab and placebo groups, respectively. The node-positive cohort continues to derive clear IDFS benefit from pertuzumab (hazard ratio 0.72 [95% CI, 0.59 to 0.87]), 6-year IDFS being 88% and 83%, respectively. Benefit was not seen in the node-negative cohort. In a subset analysis, IDFS benefit from pertuzumab showed a hazard ratio of 0.73 (95% CI, 0.59 to 0.92) for HR-positive disease and a hazard ratio of 0.83 (95% CI, 0.63 to 1.10) for HR-negative disease. Primary cardiac events remain < 1% in both the treatment groups. No new safety signals were seen. CONCLUSION: This analysis confirms the IDFS benefit from adding pertuzumab to standard adjuvant therapy for patients with node-positive HER2-positive early BC. Longer follow-up is needed to fully assess OS benefit.
引用
- Piccart M, Procter M, Fumagalli D, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. J Clin Oncol. 2021. PMID: 33539215. doi:10.1200/JCO.20.01204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。